425: Kintara Therapeutics Adjourns Special Meeting of Stockholders to October 4, 2024, to Secure Sufficient Votes for Key Proposals

Kintara Therapeutics has adjourned its Special Meeting of Stockholders to October 4, 2024, to allow more time for stockholders to vote on proposals related to the proposed merger with TuHURA Biosciences, including increasing authorized shares and reincorporating in Delaware.

Summary

• Kintara Therapeutics adjourned its Special Meeting of Stockholders on September 20, 2024, due to insufficient votes for the Charter Proposal and the Reincorporation Proposal.
• The meeting has been reconvened to October 4, 2024, to allow additional time for stockholders to vote on key proposals related to the proposed merger with TuHURA Biosciences.
• The proposals include approving the issuance of shares for the merger, a reverse stock split, increasing authorized shares to 400,000,000, approving the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan, and changing the state of incorporation to Delaware.
• Holders of 31,612,582 shares were present at the Special Meeting, constituting a quorum.
• The Adjournment Proposal was approved by stockholders with 24,945,610 votes for, 6,079,445 votes against, and 587,527 abstentions.
• Stockholders of record as of August 14, 2024, will continue to be entitled to vote at the reconvened Special Meeting.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative due to the adjournment of the special meeting, indicating potential challenges in securing stockholder approval for the merger. However, the approval of the adjournment proposal provides some optimism.

Positives

• The Adjournment Proposal was approved, allowing the company more time to secure the necessary votes for the merger-related proposals.
• A quorum was present at the initial Special Meeting, indicating sufficient stockholder interest and participation.

Negatives

• Insufficient votes were initially present to approve the Charter Proposal and the Reincorporation Proposal, necessitating the adjournment.
• The delay introduces uncertainty and potential costs associated with extending the solicitation of proxies.

Risks

• Failure to obtain stockholder approval for the proposed Merger could jeopardize the transaction.
• Delays in closing the merger could impact the anticipated cash resources of the combined company.
• Legal proceedings related to the Merger Agreement could arise.
• Competitive responses to the proposed Merger could negatively impact the company.
• Unexpected costs, charges, or expenses could result from the proposed Merger.

Future Outlook

The company is focused on securing stockholder approval for the merger with TuHURA Biosciences and completing the proposed transaction.

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards consolidation and strategic partnerships to enhance drug development pipelines and address unmet medical needs in cancer therapy.

Stakeholder Impact

• The outcome of the stockholder vote will significantly impact shareholders, as it determines the future direction of the company and the potential benefits of the merger.
• Employees of both Kintara and TuHURA may be affected by the merger, depending on the integration plans and potential synergies.
• The merger could impact patients if it leads to the development of new and improved cancer therapies.

Next Steps

• Soliciting additional proxies to secure sufficient votes for the Kintara Proposals.
• Reconvening the Special Meeting of Stockholders on October 4, 2024.
• Continuing to communicate with investors and stockholders regarding the proposed Merger.

Key Dates